KZR vs. OGI, ACTU, MGNX, PLX, ACRV, LYEL, ACRS, CRGX, GLSI, and DRUG
Should you be buying Kezar Life Sciences stock or one of its competitors? The main competitors of Kezar Life Sciences include Organigram (OGI), Actuate Therapeutics (ACTU), MacroGenics (MGNX), Protalix BioTherapeutics (PLX), Acrivon Therapeutics (ACRV), Lyell Immunopharma (LYEL), Aclaris Therapeutics (ACRS), CARGO Therapeutics (CRGX), Greenwich LifeSciences (GLSI), and Bright Minds Biosciences (DRUG). These companies are all part of the "pharmaceutical products" industry.
Kezar Life Sciences vs.
Organigram (NASDAQ:OGI) and Kezar Life Sciences (NASDAQ:KZR) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, earnings, valuation, institutional ownership, dividends, media sentiment, analyst recommendations, risk and community ranking.
In the previous week, Organigram had 11 more articles in the media than Kezar Life Sciences. MarketBeat recorded 12 mentions for Organigram and 1 mentions for Kezar Life Sciences. Kezar Life Sciences' average media sentiment score of 0.59 beat Organigram's score of 0.00 indicating that Kezar Life Sciences is being referred to more favorably in the news media.
34.6% of Organigram shares are held by institutional investors. Comparatively, 67.9% of Kezar Life Sciences shares are held by institutional investors. 0.1% of Organigram shares are held by company insiders. Comparatively, 9.3% of Kezar Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Organigram has a beta of 1, indicating that its stock price has a similar volatility profile to the S&P 500.Comparatively, Kezar Life Sciences has a beta of 0.19, indicating that its stock price is 81% less volatile than the S&P 500.
Organigram has higher revenue and earnings than Kezar Life Sciences. Organigram is trading at a lower price-to-earnings ratio than Kezar Life Sciences, indicating that it is currently the more affordable of the two stocks.
Organigram received 62 more outperform votes than Kezar Life Sciences when rated by MarketBeat users. Likewise, 70.71% of users gave Organigram an outperform vote while only 56.90% of users gave Kezar Life Sciences an outperform vote.
Kezar Life Sciences has a consensus price target of $39.50, suggesting a potential upside of 547.75%. Given Kezar Life Sciences' higher probable upside, analysts plainly believe Kezar Life Sciences is more favorable than Organigram.
Kezar Life Sciences has a net margin of 0.00% compared to Organigram's net margin of -28.58%. Organigram's return on equity of -11.68% beat Kezar Life Sciences' return on equity.
Summary
Organigram beats Kezar Life Sciences on 11 of the 18 factors compared between the two stocks.
Get Kezar Life Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for KZR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Kezar Life Sciences Competitors List
Related Companies and Tools
This page (NASDAQ:KZR) was last updated on 2/11/2025 by MarketBeat.com Staff
